Cargando…
Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy
Accumulating evidence demonstrates the decisive role of the gut microbiota in determining the effectiveness of anticancer therapeutics such as immunogenic chemotherapy or immune checkpoint blockade in preclinical tumor models, as well as in cancer patients. In synthesis, it appears that a normal int...
Autores principales: | Daillère, Romain, Derosa, Lisa, Bonvalet, Mélodie, Segata, Nicola, Routy, Bertrand, Gariboldi, Manuela, Budinská, Eva, De Vries, I. Jolanda M., Naccarati, Alessio Gordon, Zitvogel, Valérie, Caldas, Carlos, Engstrand, Lars, Loilbl, Sibylle, Fieschi, Jacques, Heinzerling, Lucie, Kroemer, Guido, Zitvogel, Laurence |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466862/ https://www.ncbi.nlm.nih.gov/pubmed/32934879 http://dx.doi.org/10.1080/2162402X.2020.1774298 |
Ejemplares similares
-
COVID-19: a challenge for oncology services
por: Routy, Bertrand, et al.
Publicado: (2020) -
The intimate relationship between gut microbiota and cancer immunotherapy
por: Elkrief, Arielle, et al.
Publicado: (2018) -
Boosting the immunotherapy response by nutritional interventions
por: Zitvogel, Laurence, et al.
Publicado: (2022) -
Trial watch: IDO inhibitors in cancer therapy
por: Le Naour, Julie, et al.
Publicado: (2020) -
Trial watch: STING agonists in cancer therapy
por: Le Naour, Julie, et al.
Publicado: (2020)